Evidence map›Paper›PMID 37094724›Full record

ArticleBioorganic & medicinal chemistry letters2023

Identification of a novel spirocyclic Nek2 inhibitor using high throughput virtual screening.

Ashif I Bhuiyan, Athena H Choi, Sarbani Ghoshal, Ugochi A Adiele, Dibyendu Dana, Jun Yong Choi, Karl R Fath, Tanaji T Talele, Sanjai K Pathak

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Role of NEK2 in tumorigenesis and tumor progression.Trends in molecular medicine · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Ashif I BhuiyanQueens College of The City University of New York, Chemistry and Biochemistry Department, 65-30 Kissena Blvd, Flushing, NY 11367, USA; Chemistry Doctoral Program, The Graduate Center of The City University of New York, 365 5th Ave, New York, NY 10016, USA.
Athena H ChoiBrooklyn Technical High School, 29 Fort Greene Place, Brooklyn, NY 11217, USA.
Sarbani GhoshalQueensborough Community College of the City University of New York, 222-02 56(th) Avenue, Bayside, NY 11364, USA.
Ugochi A AdieleDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, USA.
Dibyendu DanaQueens College of The City University of New York, Chemistry and Biochemistry Department, 65-30 Kissena Blvd, Flushing, NY 11367, USA.
Jun Yong ChoiQueens College of The City University of New York, Chemistry and Biochemistry Department, 65-30 Kissena Blvd, Flushing, NY 11367, USA; Chemistry Doctoral Program, The Graduate Center of The City University of New York, 365 5th Ave, New York, NY 10016, USA; Biochemistry Doctoral Program, The Graduate Center of The City University of New York, 365 5th Ave, New York, NY 10016, USA.
Karl R FathQueens College of The City University of New York, Department of Biology, 65-30 Kissena Blvd, Flushing, NY 11367, USA; Biochemistry Doctoral Program, The Graduate Center of The City University of New York, 365 5th Ave, New York, NY 10016, USA.
Tanaji T TaleleDepartment of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, USA.
Sanjai K PathakQueens College of The City University of New York, Chemistry and Biochemistry Department, 65-30 Kissena Blvd, Flushing, NY 11367, USA; Chemistry Doctoral Program, The Graduate Center of The City University of New York, 365 5th Ave, New York, NY 10016, USA; Biochemistry Doctoral Program, The Graduate Center of The City University of New York, 365 5th Ave, New York, NY 10016, USA. Electronic address: Sanjai.Kumar@qc.cuny.edu.
Queens College, CUNY · USSt. John's University · USBrooklyn Technical High School · USQueensborough Community College, CUNY · US

Funding

Development of Allosteric Modulators of Phosphatidylinositol 3-KinaseSC2GM130470 · NIGMS · QUEENS COLLEGE · PI CHOI, JUN-YONG · 2019 to 2021
$462k
Development of Light-activatable Probes and Dual-Action Inhibitors of Nek2 KinaseR15CA243109 · NCI · QUEENS COLLEGE · PI PATHAK, SANJAI KUMAR · 2019 to 2019
$381k
NCI NIH HHS R15 CA243109NIGMS NIH HHS SC2 GM130470
6 · The paper itself

Abstract

NIMA Related Kinase 2 (Nek2) kinase is an attractive target for the development of therapeutic agents for several types of highly invasive cancers. Despite this, no small molecule inhibitor has advanced to the late clinical stages thus far. In this work, we have identified a novel spirocyclic inhibitor (V8) of Nek2 kinase, utilizing a high-throughput virtual screening (HTVS) approach. Using recombinant Nek2 enzyme assays, we show that V8 can inhibit Nek2 kinase activity (IC

Indexed as

NIMA-Related KinasesCell Line, TumorHumansLung NeoplasmsModels, MolecularPhosphorylationStructure-Activity RelationshipNEK2 protein, humanNIMA-Related KinasesCytotoxicity of Nek2 inhibitorNek2 and Akt/PI3K signalingNek2 hinge pharmacophoreNek2 HTVSNek2 inhibitorNek2 kinase

Identifiers

PMID37094724
PMCPMC10246433
OpenAlexW4366748307

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.